The 3′UTR region of the DNA repair gene PARP-1 May increase the severity of COVID-19 by altering the binding of antiviral miRNAs

[1]  S. Ghafouri-Fard,et al.  miRNA expression in COVID-19 , 2022, Gene Reports.

[2]  Wenlong Liu,et al.  Association between the genetic variants of base excision repair pathway genes and allergic rhinitis susceptibility in Chinese children , 2022, The World Allergy Organization journal.

[3]  Ling-Ya Chiu,et al.  PARP-1 regulates inflammasome activity by poly-ADP-ribosylation of NLRP3 and interaction with TXNIP in primary macrophages , 2022, Cellular and Molecular Life Sciences.

[4]  A. Banerjee,et al.  The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review , 2021, Virus Research.

[5]  A. Khodadadi,et al.  miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19 , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  Chen-Yu Zhang,et al.  Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients , 2021, Signal Transduction and Targeted Therapy.

[7]  A. Jebali,et al.  The miRNA neuroinflammatory biomarkers in COVID-19 patients with different severity of illness , 2021, Neurologia.

[8]  A. Dursun,et al.  Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID‐19: A case study , 2021, Journal of medical virology.

[9]  Aydın Demiray,et al.  Serum microRNA signature is capable of predictive and prognostic factor for SARS-COV-2 virulence , 2021, Turkish Journal of Biochemistry.

[10]  M. Boshtam,et al.  The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy , 2021, International journal of molecular sciences.

[11]  N. Lévêque,et al.  The Antiviral Activities of Poly-ADP-Ribose Polymerases , 2021, Viruses.

[12]  J. Rajawat,et al.  Role of Poly(ADP-ribose) polymerase (PARP1) in viral infection and its implication in SARS-CoV-2 pathogenesis. , 2021, Current drug targets.

[13]  S. Mokale,et al.  Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs , 2020, Virology.

[14]  F. Martelli,et al.  The epigenetic implication in coronavirus infection and therapy , 2020, Clinical epigenetics.

[15]  R. Zhou,et al.  PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China , 2020, Asian Pacific journal of cancer prevention : APJCP.

[16]  G. Sancesario,et al.  Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington’s Disease , 2020, Cells.

[17]  R. Higgs,et al.  Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[18]  C. Szabó,et al.  Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept , 2020, American journal of respiratory cell and molecular biology.

[19]  F. Novikov,et al.  Molecular basis of COVID-19 pathogenesis , 2020, Russian Chemical Reviews.

[20]  A. Badawy.  Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide , 2020, Bioscience reports.

[21]  G. Richards,et al.  COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity , 2020, Medical Hypotheses.

[22]  T. Swartz,et al.  Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.

[23]  E. Grzybowska,et al.  Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients , 2020, Scientific Reports.

[24]  C. E. Condrat,et al.  MicroRNA Involvement in Signaling Pathways During Viral Infection , 2020, Frontiers in Cell and Developmental Biology.

[25]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[26]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[27]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[28]  S. Perlman,et al.  Murine coronavirus infection activates AhR in an IDO1-independent manner contributing to cytokine modulation and pro-viral TiPARP expression. , 2019, Journal of virology.

[29]  L. Ming,et al.  PARP-1 Variant Rs1136410 Confers Protection against Coronary Artery Disease in a Chinese Han Population: A Two-Stage Case-Control Study Involving 5643 Subjects , 2017, Front. Physiol..

[30]  A. Naccarati,et al.  MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis , 2017, Mutagenesis.

[31]  Ziying Liu,et al.  PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes , 2017, Genes & development.

[32]  Jincun Zhao,et al.  The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection , 2016, mBio.

[33]  A. Boulares,et al.  PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice , 2015, Clinical science.

[34]  Fang Li,et al.  Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies , 2014, Journal of Virology.

[35]  B. Stockinger,et al.  The aryl hydrocarbon receptor: multitasking in the immune system. , 2014, Annual review of immunology.

[36]  Y. Selim,et al.  Investigation of poly (ADP-ribose) polymerase-1 genetic variants as a possible risk for allergic rhinitis. , 2014 .

[37]  F. Aksoy,et al.  Investigation of poly (ADP-ribose) polymerase-1 genetic variants as a possible risk for allergic rhinitis. , 2014, Genetic testing and molecular biomarkers.

[38]  L. Traber,et al.  Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model. , 2012, Burns : journal of the International Society for Burn Injuries.

[39]  D. Bishop,et al.  The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes , 2011, Carcinogenesis.

[40]  S. Leib,et al.  SNPs in DNA repair genes associated to meningitis and host immune response. , 2011, Mutation research.

[41]  Oliver Popp,et al.  Enzyme characteristics of recombinant poly(ADP-ribose) polymerases-1 of rat and human origin mirror the correlation between cellular poly(ADP-ribosyl)ation capacity and species-specific life span , 2010, Mechanisms of Ageing and Development.

[42]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[43]  K. Murthy,et al.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway , 2010, Critical care.

[44]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[45]  C. Tsai,et al.  Evaluation of the poly(ADP‐ribose) polymerase‐1 gene variants in Alzheimer's disease , 2010, Journal of clinical laboratory analysis.

[46]  Claus Scheidereit,et al.  A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. , 2009, Molecular cell.

[47]  H. Weiner,et al.  Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE , 2009, Nature Immunology.

[48]  G. Tezcan,et al.  The Ala Allele at Val762Ala Polymorphism in Poly(ADP-ribose) Polymerase-1 (PARP-1) Gene is Associated with a Decreased Risk of Asthma in a Turkish Population , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[49]  C. Jopling.  Regulation of hepatitis C virus by microRNA-122. , 2008, Biochemical Society transactions.

[50]  B. Ludewig,et al.  Mouse Hepatitis Virus Liver Pathology Is Dependent on ADP-Ribose-1″-Phosphatase, a Viral Function Conserved in the Alpha-Like Supergroup , 2008, Journal of Virology.

[51]  Zhao-Qi Wang,et al.  PARP1 Val762Ala polymorphism reduces enzymatic activity. , 2007, Biochemical and biophysical research communications.

[52]  T. Ahola,et al.  Structural and Functional Basis for ADP-Ribose and Poly(ADP-Ribose) Binding by Viral Macro Domains , 2006, Journal of Virology.

[53]  R. Swanson,et al.  Poly(ADP‐ribose) polymerase‐1 activation in a primate model of multiple sclerosis , 2005, Journal of neuroscience research.

[54]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[55]  M. Hottiger,et al.  Transcriptional Coactivation of Nuclear Factor-κB-dependent Gene Expression by p300 Is Regulated by Poly(ADP)-ribose Polymerase-1* , 2003, Journal of Biological Chemistry.

[56]  E. Wouters,et al.  Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. , 2003, Free radical biology & medicine.

[57]  Zhao-Qi Wang,et al.  Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. , 2001, Biochimica et biophysica acta.

[58]  R. Andriantsitohaina,et al.  Resistance to endotoxic shock as a consequence of defective NF‐κB activation in poly (ADP‐ribose) polymerase‐1 deficient mice , 1999, The EMBO journal.

[59]  A. Bürkle,et al.  Poly(ADP-ribose) polymerase activity in mononuclear leukocytes of 13 mammalian species correlates with species-specific life span. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  T. Sugimura,et al.  Characterization of a putative promoter region of the human poly(ADP-ribose) polymerase gene: structural similarity to that of the DNA polymerase beta gene. , 1990, Biochemical and Biophysical Research Communications - BBRC.